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Abstract
The serotonin type 3 receptor (5-HT3R) is a ligand-gated ion channel that mediates fast synaptic
transmission in the central and peripheral nervous systems. The 5-HT3R is a therapeutic target,
and the clinically available drugs ondansetron and granisetron inhibit receptor activity. Their
inhibitory action is through competitive binding to the native ligand binding site, although the
binding orientation of the drugs at the receptor has been a matter of debate. Here we
heterologously express mouse 5-HT3A receptors in Xenopus oocytes and use unnatural amino
acid mutagenesis to establish a cation-π interaction for both ondansetron and granisetron to
tryptophan 183 in the ligand binding pocket. This cation-π interaction establishes a binding
orientation for both ondansetron and granisetron within the binding pocket.
INTRODUCTION
The serotonin type 3 receptor (5-HT3R)1–2 is a ligand-gated ion channel in the Cys-loop
(pentameric) family of receptors, which also includes GABAA, glycine, and nicotinic
acetylcholine (nACh) receptors.3 The 5-HT3 receptor is a cation selective channel found in
the central and peripheral nervous systems. Conduction occurs through a central pore,
formed by the pseudo-symmetric assembly of five subunits (Figure 1). There are five known
5-HT3R subunits (A – E),4 with the best characterized receptors being the homomeric 5-
HT3A receptor (5-HT3AR) and the heteromeric 5-HT3AB receptors.5
The 5-HT3 receptor has been validated as a therapeutic target—antagonists are currently
used to control chemotherapy-induced nausea, as well as to treat irritable bowel
syndrome.6–7 Beyond current clinical uses, there is evidence that compounds targeting the 5-
HT3 receptor could be useful for the treatment of a variety of disorders including
schizophrenia and substance abuse, as well as management of pain associated with, for
example, fibromyalgia. Prototype antagonists of the 5-HT3 receptor are ondansetron
(Zofran®) and granisetron (Kytril®) (Figure 2a).
There is no high-resolution structure of the 5-HT3 receptor. There is, however, structural
information from a number of sources, including cryoelectron microscopy images of the
nACh receptor,8 high resolution structures of the homologous acetylcholine binding
protein,9 and the recently published x-ray structure of the glutamate-gated chloride channel
from C. elegans, GluCl.10 These data, along with homology modeling and biochemical
studies, have provided a putative binding site for 5-HT3 antagonists that coincides with the
binding site of the native agonist, serotonin (5-HT, Figure 2b). This binding site is formed
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by a series of β-strands and connecting loops (labeled A-F), with loops A-C contributed by
the “principal,” and β-strands D-F contributed by the “complementary” subunit (Figure 1).
Docking studies using homology models have found multiple energetically favorable poses
of the antagonist granisetron within this binding site, and the orientation of the drug and the
identities of the interacting residues are not constant across poses.11–14 For example,
Thompson et. al. reported two classes of poses of granisetron.13 In one class, the cationic
ammonium was oriented between Trp183 (loop B) and Tyr234 (loop C), while the aromatic
indazole was oriented between Trp90 (β-strand D) and Phe226 (loop C). In the second class
of poses, this orientation was reversed, with the cationic ammonium towards Trp90 and
Phe226. Experimentally, both Trp183 and Trp90 have been established to be important for
granisetron binding. In other experimental work, Yan and White found that Trp90 is
important for both ondansetron and granisetron binding, and they interpreted their results as
providing evidence that the cationic ammonium of granisetron was oriented towards
Trp90.14
The accepted pharmacophore model for 5-HT3R includes an amine group on the ligand. Past
studies in our laboratory have established the primary amine of 5-HT to make a cation-π
interaction with a conserved tryptophan residue on loop B (Trp183).15 Mutation of Trp183
(as well as Trp90, Glu129 (loop A), and Tyr234) to alanine abolishes binding of
[3H]granisetron.13 Taken together, these results identify Trp183 as a prime candidate for
more detailed studies. Moreover, the docking studies of Thompson et. al. provide us with
testable guidelines as to other possible interactions; specifically, with Trp90.13 In the present
work, we set out to better understand the binding of the high affinity antagonistic drugs
ondansetron and granisetron to the 5-HT3AR. The cationic center of granisetron is a tertiary
ammonium ion in a granatane moiety (pKa = 9.6), but ondansetron has a structurally distinct
N-akylimidazolium moiety (pKa = 7.4).16 We sought to determine if this structural
difference leads to different binding orientations for the two drugs.
RESULTS AND DISCUSSION
Ondansetron and Granisetron Schild Analysis
In examining the interaction of a competitive antagonist with a receptor, equilibrium
dissociation constants, Kb, provide the most direct indicator of binding interactions.17
Previous reports have indicated that granisetron and ondansetron act competitively with 5-
HT at the 5-HT3AR.2, 18 Both antagonists bind reversibly, in that after a several minute
washout of either ondansetron or granisetron, agonist responses recovered completely.
Previous studies have established dissociation rate constants of 0.58 min−1 for ondansetron,
and 0.13 min−1 for granisetron,19 consistent with our observations. It has also been shown
that granisetron and ondansetron directly compete with each other for the same binding
site.19 We attempted to determine Kb for ondansetron and granisetron using Schild (dose-
ratio) analysis;17 this requires measurements of dose-response relationships (Figure 3).
Schild analysis of ondansetron applied to preparations of rat vagus nerves gave parallel
shifts, indicative of a competitive interaction, but efforts to perform similar studies with
granisetron were not successful.20 As shown in Figure 3, during our standard 15 second
agonist application (see Methods), the inhibition by ondansetron and granisetron was
insurmountable by 5-HT—full receptor activity could not be restored even with high
concentrations of 5-HT. We attribute the insurmountable inhibition to the slow off rates. The
granisetron data are better behaved than the ondansetron data, but in either case we face a
requirement of agonist applications several minutes in duration. However, the 5-HT3AR
desensitizes on this time scale before full equilibrium is achieved. Thus, for the high-affinity
5-HT3AR antagonists ondansetron and granisetron, determination of true Kb by functional
measurements is not possible.
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Thus, the concentration required for 50% receptor inhibition (IC50) was the only viable
functional measurement, and so modified procedures were developed to render IC50 values a
good direct measure of antagonist binding. The IC50 measurement is taken in the context of
multiple equilibria, including both agonist and antagonist binding/dissociation,
conformational changes in the protein, and the “gating” equilibria between the open the
closed states of the receptor. We sought to reduce the contribution from changes in agonist
potency, while retaining an index of antagonist potency. When evaluating competitive
antagonists, it is useful to consider more than one agonist, so that one can be sure that IC50
determinations are not distorted by agonist-receptor interacts. To determine IC50 values for
ondansetron and granisetron, we studied both 5-HT and an additional agonist, meta-
chlorophenylbiguanide (mCPBG, Figure 2b).21
Agonist behavior at Trp183 and Trp90. The effective concentrations for 50% receptor
activation (EC50) were determined for both the native agonist 5-HT, as well as the potent
partial agonist mCPBG. The EC50 values were also determined for a series of fluorinated
tryptophan derivatives (Figure 2c) introduced by nonsense suppression at Trp183 (Table 1).
The EC50 values confirm the previously reported15 cation-π interaction for 5-HT at Trp183.
Interestingly, we have recently found that mCPBG does not respond to fluorination at
Trp183 in the same manner as 5-HT,22 and the data of Table 2 produced for this work
confirm that result. Detailed experiments and discussion concerning the activation of 5-HT3
receptors by mCPBG will be presented in a separate publication.22 For the present purposes,
the key point is that mCPBG responds for fluorination at Trp183 differently than 5-HT.
When the fluorinated tryptophans F3Trp and F4Trp were installed at Trp90, both 5-HT and
mCPBG show a gain of function. These data are consistent with no cation-π interaction for
5-HT or mCPBG with Trp90.
Ondansetron and Granisetron at Trp183 and Trp90
An important aspect of the complex nature of measuring IC50 in receptors is the
concentration of agonist used for receptor activation. For a competitive interaction, a
measured IC50 value will depend on the agonist concentration.17 In order to make
meaningful comparisons of IC50 values across mutant receptors, the concentration of agonist
used was kept at a constant value of twice EC50. The choice of a constant ratio of twice
EC50 was made to ensure sufficient signal, even in cases of low receptor expression. We
also emphasize that the series of mutations being introduced represents a much more subtle
variation in structure than is possible with conventional mutagenesis. This provides further
confidence that no dramatic changes in receptor-antagonist interactions are occurring in the
study. We also exploited the difference in the binding modes of 5-HT and mCPBG to
control for possible artificial trends in IC50 measurements.
Dose-response/inhibition relations were determined for ondansetron and granisetron, using
both 5-HT and mCPBG as agonists, with representative voltage-clamp traces shown in
Figure 4. These measurements were performed on the wild type 5-HT3AR as well as for a
series of fluorinated tryptophan derivatives at Trp183. Agonist concentrations were 2 ×
EC50 for each agonist at each receptor, and data were fit to the Hill equation (Figure 4). The
resultant IC50 values are presented in Table 2. Inhibition data for F4Trp could not be
gathered using 5-HT as the agonist, because of channel block by high concentrations of 5-
HT.
The effect of fluorine substitution in modulating a cation-π interaction has been well
established.15, 23–25 For both ondansetron and granisetron, incremental substitutions of
fluorine to Trp183 increased IC50. As in previous studies of fluorination trends, IC50 fold-
shift values were plotted against cation-π binding ability of fluorinated indoles, producing
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the “fluorination plots” shown in Figure 5. Ondansetron inhibition linearly correlates with
the energy of cation-π binding, regardless of whether 5-HT or mCPBG was used as an
agonist. Granisetron also displayed a strong correlation with respect to degree of
fluorination, regardless of agonist identity.
We interpret these results as establishing a cation-π interaction between each drug and
Trp183. The results of Figure 5 highlight the value of having two distinct agonists to
evaluate an antagonist. With 5-HT as the agonist, we see linear fluorination plots for the
antagonists. The agonist alone, 5-HT, shows a similar plot in a study of its EC50. We
corrected for this by always using a 5-HT does of 2 × EC50 for the particular fluorination
mutant. Nevertheless, there could be concern about deconvoluting the effect of fluorination
on the agonist vs. the antagonist. With mCPBG as the agonist, there is no such concern, as it
does not respond to fluorination at Trp183 in a manner consistent with a cation-π
interaction. Thus, the fluorination trends seen in Figure 5 can confidently be assigned as
reflecting the response of the antagonist to the mutation. We also note that the fluorination
effect remains regardless of the structural identity of the cation. Ondansetron, with a N-
akylimidazolium moiety, and granisetron, with a tertiary ammonium, show similar trends at
the same residue, which is evidence that their binding orientations are similar.
While the general trends in our data are clear, the detailed behaviors of the F2Trp unnatural
amino acids present interesting details. In the fluorination plots, 5,7-F2Trp, a residue that we
have used extensively, deviates from the line set by the other derivatives, especially for
granisetron. The effect is evident, but much less pronounced, in studies of ondansetron. We
considered the possibility that an additional unique, perhaps steric, feature of 5,7-F2Trp was
influencing the analysis.
As such, we prepared 4,7-F2Trp (Scheme 1), which should have the same cation-π binding
ability, but different steric requirements. Synthesis began by direct formation of 4,7-
difluoroindole (1) in a Bartoli reaction between the appropriate nitrodifluorobenzene and
vinyl magnesium bromide.26–27 In a sequence similar to Gilchrist et. al.28 the difluoroindole
(1) was then reacted with ethyl-3-bromo-2-hydroxyiminopropanoate to yield the oxime (2),
which was then reduced using aluminum/mercury amalgam. The amine of the resulting
amino acid ester was protected with the photocleavable 2-nitroveratryloxycarbonyl
(NVOC), and the ester hydrolyzed with sodium hydroxide. Conversion to the cyanomethyl
ester (3) gave material suitable for acylation of the dinucleotide dCA, and for preparation of
tRNA necessary for incorporation into the 5-HT3R (methods described previously).29 The
unnatural amino acid prepared by this route is, of course, racemic, but only the natural L
configuration will be incorporated; the ribosome of the Xenopus oocyte in effect performs a
kinetic resolution.
From an electrostatic point of view, 5,7-F2Trp and 4,7-F2Trp are, to first order,
indistinguishable, and so they should be equivalent in a cation-π interaction. This is born out
in the EC50 data for serotonin (Table 1), where the two F2Trp residues differ only by a factor
of two, while the full fluorination series spans more than a factor of 150. In contrast, the
EC50 values for mCPBG differ by 8-fold for the two F2Trps. Recall that mCPBG does not
make a cation-π interaction to the Trp. This again suggests that specific steric interactions at
Trp183 may be involved.
In the granisetron IC50 plots, 4,7-F2Trp gives a quite different response than 5,7-F2Trp. We
have suggested the possibility of a special steric effect with 5,7-F2Trp, but 5,6,7-F3Trp and
4,5,6,7-F4Trp both have fluorine atoms at the positions in 5,7-F2Trp, yet follow the trend
indicative of electrostatics as the major determinant to binding. As such, we cannot provide
a simple rationalization of the behaviors of the two difluoro-Trp residues. Nevertheless, the
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consistent linear trend of Trp, F1Trp, F3Trp, and F4Trp (Figure 5) provides compelling
evidence for a cation-π interaction to Trp183 for both granisetron and ondansetron.
Both ondansetron and granisetron either increase their potencies or retain their potencies
when Trp90 is mutated to F3Trp or F4Trp respectively. This holds for both 5-HT and
mCPBG used as the agonist, which indicates no cation-π interaction at that site. A loss of
potency would be expected if a cation-π interaction were present. We noted above that Yan
and White concluded that Trp90 is important for binding of ondansetron and granisetron.14
Based on the observation that granisetron and ondansetron responded differently to a W90F
mutation, the authors concluded that the bicyclic amine of granisetron interacts with Trp90.
Our results position this moiety in contact with Trp183, and we conclude that the importance
of Trp90 is for reasons other than a cation-π interaction.
The present results provide evidence that the cationic centers of ondansetron and granisetron
are oriented towards Trp183, and not towards Trp90. Establishing a cation-π interaction
with ondansetron and granisetron at Trp183 determines a binding orientation for these
antagonists. Docking studies of granisetron performed in other laboratories have generated a
series of poses, some which are consistent with the cation pointed towards Trp183. Our data
provide evidence that these poses are the most viable, while those with the cation pointed
away from Trp183 are not likely to be relevant.
Summary
We have identified a cation-π interaction with the antagonists ondansetron and granisetron
to Trp183 in the 5-HT3AR. This interaction is consistent with the binding mode of 5-HT,
but not mCPBG. The use of agonists with alternate binding modes validates our data as
direct measurements of ondansetron and granisetron. Thus, the common antagonists follow
the basic pharmacophore established by 5-HT, and not the structurally dissimilar agonist
mCPBG.
METHODS
Procedures for incorporating unnatural amino acids, expressing receptors in Xenopus
oocytes, and characterization by electrophysiology followed established protocols.29
Protein expression in Xenopus oocytes
The mouse 5-HT3A receptor in the pGEMHE vector was linearized with the restriction
enzyme Sbf I (New England Biolabs). mRNA was prepared by in vitro transcription using
the mMessage Machine T7 kit (Ambion). Unnatural mutations were introduced by the
standard Stratagene QuickChange protocol using a TAG mutation at W183 and W90. Stage
V-VI Xenopus laevis oocytes were injected with mRNA. Each cell was injected with 50 nL
containing only mRNA (5 ng) for wild type 5-HT3AR or a mixture of mRNA (5–32 ng,
typically ~12 ng) and tRNA (18–30 ng, typically ~18 ng) for unnatural amino acid.
Uncharged full length tRNA was injected as a negative control.
Electrophysiology—Electrophysiological experiments were performed 24–48 hours after
injection using the OpusXpress 6000A instrument (Axon Instruments) in two-electrode
voltage clamp mode at a holding potential of −60 mV. The running buffer was Ca2+-free
ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM HEPES, pH 7.5).
Serotonin hydrochloride (5-HT) was purchased from Alfa Aesar. 1-(3-
Chlorophenyl)biguanide (mCPBG) was purchased from Sigma-Aldrich. Granisetron
hydrochloride and ondansetron hydrochloride were purchased from Tocris Bioscience.
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For EC50 determinations, oocytes were superfused with running buffer at 1 mL/min for 30s
before application of 5-HT or mCPBG for 15 s followed by a 116 s wash with the running
buffer. Data were sampled at 125 Hz and filtered at 50 Hz. Dose-response data were
obtained for ≥ 9 concentrations of 5-HT or mCPBG on ≥ 9 cells. All EC50 and Hill
coefficient values were obtained by fitting dose-response relations to the Hill equation (Inorm
= 1/[1 + (EC50/[agonist])n]) and are reported as means ± standard error of the fit.
For IC50 determinations, oocyte response to either 5-HT or mCPBG at 2 × EC50 for each
receptor was measured before application of antagonists by application of the agonist for 15
s followed by 116 s of wash with the running buffer. Granisetron or ondansetron doses were
then pre-applied and the oocyte allowed to incubate for 60 s, followed by application of a
mixture of the antagonist dose with 5-HT or mCPBG at 2 fold EC50. The oocytes were then
washed with the running buffer for 116 s. Every 4 antagonist doses, the oocytes were
washed for 10 min, and oocyte response reconfirmed using either 5-HT or mCPBG at 2 fold
EC50. Oocytes that did not give consistent responses to 5-HT or mCPBG alone throughout
the experiment were discarded. Dose-response data were obtained for ≥ 8 concentrations of
granisetron or ondansetron on ≥ 8 cells. All EC50 and Hill coefficient values were obtained
by fitting Dose-response relations to the Hill equation (Inorm = 1/[1 + (EC50/[antagonist])n])
and are reported as means ± standard error of the fit.
For Schild analysis, the protocol for EC50 determinations was repeated with the following
changes: during the course of the experiment after each minimal EC50 curve was
determined, running buffer containing granisetron or ondansetron was used for the
subsequent EC50 determinations. Agonist applications in the subsequent EC50
determinations contained the same concentration of antagonist as the running buffer.
Synthesis of 3 (Scheme 1)
4,7-Difluoroindole (1)—A solution of 3.5 mL (32.3 mmol) of 1,4-difluoro-2-nitrobenzene
in 30 mL of dry THF was cooled in an acetone/dry ice bath to −78 °C under argon. A 1 M
solution of vinylmagnesium bromide in THF (100 mL, 100 mmol, 3 eq.) was added via
cannula over 20 minutes. The reaction was stirred for 1 hour at −78 °C. Reaction quenched
by the addition of 20 mL of saturated aq. NH4Cl. Upon warming to room temperature, 20
mL of water was added, which forms a thick emulsion. Reaction filtered through a layer of
sand and washed copiously with ethyl acetate. The organic layer was separated and dried
over Na2SO4. The solvent was removed under reduced pressure to yield a brown oil
containing multiple compounds. Purification by silica gel chromatography using a gradient
of 3% to 10 % ethyl acetate in hexanes yielded a slightly volatile amber oil. 871 mg (18%).
Silica TLC (4% EtOAc in hexanes) Rf = 0.26, stains red/pink using p-anisaldehyde. 1H
NMR (300 MHz, CDCl3): δ 8.47 (br, 1H), 7.18 (t, J = 2.8 Hz, 1H), 6.78 (ddd, J = 10.3, 8.6,
3.5 Hz, 1H), 6.71 – 6.60 (m, 2H). 19F NMR (282 MHz, CDCl3): δ −124.1 – −129.8 (m),
−139.4 – −142.3 (m). 13C NMR (126 MHz, CDCl3): δ 152.2 (dd, J = 239, 2.4 Hz), 145.8
(dd, J = 238.6, 3.0 Hz), 126.0 (dd, J = 15.9, 11.5 Hz), 124.7, 119.9 (dd, J = 24.9, 5.7 Hz),
106.4 (dd, J = 18.9, 8.2 Hz), 103.9 (dd, J = 18.9 8.2 Hz), 99.8. HRMS EI(+) m/z for
C8H5NF2 found 153.0395, calculated 153.0390 (M+•).
Ethyl 3-(4,7-difluoro-1H-indol-3-yl)-2-(hydroxyimino)propanoate (2)—A solution
of 424 mg (2.8 mmol, 2 eq.) of 4,7-difluoroindole in 10 mL CH2Cl2 was added to 290 mg
(1.4 mmol, 1 eq.) of ethyl 3-bromo-2-(hydroxyimino)propanoate and 205 mg (1.9 mmol, 1.4
eq.) of Na2CO3. The mixture was stirred overnight under argon at room temperature. The
reaction was diluted with 50 mL of CH2Cl2 and 50 mL of ethyl acetate, washed with 50 mL
of water, 50 mL brine. The organic phase was separated and dried over Na2SO4. Purification
performed by silica chromatography, gradient 25% to 40% EtOAc in hexanes to yield a
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white solid. 195 mg (50%). 1H NMR (300 MHz, CD3CN): δ 9.93 (s, 1H), 9.64 (br, 1H),
7.01 (m, 1H), 6.81 (ddd, J = 10.5, 8.5, 3.5 Hz, 1H), 6.67 (ddd, J = 10.7, 8.5, 3.2 Hz, 1H),
4.21 (q, J = 7.2 Hz, 2H), 4.12 (d, J = 1.1 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H). 19F NMR (282
MHz, CD3CN): δ −130.99 – −131.20 (m), −141.02 – −141.19 (m). 13C NMR (126 MHz,
CDCl3): δ 164.80, 153.77 (dd, J = 240.4, 2.3 Hz), 152.58, 146.84 (dd, J = 238.1, 2.9 Hz),
127.18 (dd, J = 16.4, 12.1 Hz), 125.12, 119.55 (dd, J = 22.1, 5.7 Hz), 110.05 (dd, J = 3.7, 1.6
Hz), 106.94 (dd, J = 19.7, 9.1 Hz), 104.42 (dd, J = 22.9, 7.5 Hz), 62.28, 21.96 (d, J = 3.1
Hz), 14.33. HRMS FAB(+) m/z for C13H13O3N2F2 found 283.0888, calculated 283.0894
(M+H).
N-(2-nitroveratryloxycarbonyl)-4,7-difluorotryptophan cyanomethyl ester (3)—
In a beaker 1.5 g of 8–20 mesh aluminum stirred under 15 mL of 2 M NaOH for 5 minutes.
After decanting, the aluminum was rinsed with water and 15 mL of a 2% HgCl2 solution
was added and stirred slowly. The solution was decanted after formation of the Hg-Al (~10
minutes) and added to 195 mg (0.69 mmol) of 2 in 20 mL of 9:1 dioxane:water. The reaction
was stirred slowly at room temperature overnight (~24 hours). The reaction was filtered
through fluted paper, then applied to a silica plug, eluting with EtOAc followed by 4%
MeOH in EtOAc. After concentration under reduced pressure, the resulting oil was used
directly. The oil was dissolved in 20 mL of 1:1 THF:water and 151 mg of Na2CO3 (1.42
mmol) and 248 mg of 4,5-dimethoxy-2-nitrobenzyl chloroformate (0.9 mmol) were added.
The reaction was stirred at room temperature for 3 hours, followed by dilution with 20 mL
CH2Cl2 and 20 mL 1 N HCl. The organic phase was separated, washed with brine, and dried
over Na2SO4. Initial purification by silica chromatography 20% to 40% EtOAc in hexanes
did not separate the product from nitroveratryl side products. This mixture was dissolved in
3 mL dioxane and 3 mL 2N NaOH and stirred for 15 minutes. Reaction quenched with 6 mL
1 N HCl and diluted with 20 mL EtOAc. The organic phase was separated, and the aqueous
phase washed with 20 mL CH2Cl2. The combined organic phases were dried over Na2SO4,
concentrated under reduced pressure, and filtered through a silica plug eluting EtOAc
followed by 0.5 % acetic acid in EtOAc. This residue (~35 mg, 0.07 mmol) was dissolved in
1 mL DMSO, and added to a reaction flask containing 0.5 mL of chloroacetonitrile (7.9
mmol), and 0.5 mL of triethylamine (3.6 mmol). The reaction was allowed to stir at room
temperature for 5 hours. The reaction was poured onto a dry column of silica and eluted with
EtOAc to recover 23 mg of a yellow solid (6%, 4 steps). 1H NMR (300 MHz, DMSO-d6): δ
11.71 (s, 1H), 8.21 (d, J = 7.7 Hz, 1H), 7.68 (s, 1H), 7.23 (d, J = 2.0 Hz, 1H), 7.09 (s, 1H),
6.92 – 6.80 (m, 1H), 6.74 – 6.62 (m, 1H), 5.39 – 5.21 (m, 2H), 4.99 (s, 2H), 4.48 – 4.35 (m,
1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.32 – 2.99 (m, 2H). 19F NMR (282 MHz, DMSO-d6): δ
−130.18 (dd, J = 22.4, 9.9 Hz), −138.53 (ddd, J = 22.6, 10.6, 3.1 Hz). 13C NMR (126 MHz,
DMSO-d6): δ 171.56, 156.03, 153.83, 152.62 (d, J = 239.6 Hz), 148.15, 146.10 (dd, J =
238.5, 2.2 Hz), 139.55, 128.09, 126.70 (dd, J = 16.1, 12.2 Hz), 126.36, 118.82 – 118.30 (m),
116.08, 110.61, 109.18, 108.59, 106.23 (dd, J = 18.8, 8.7 Hz), 103.90 – 103.23 (m), 63.15,
56.55, 55.30, 49.97, 27.84. HRMS FAB(+) m/z for C23H20O8N4F2 found 518.1271,
calculated 518.1249 (M+•).
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Figure 1.
Basic layout of a Cys-loop (pentameric) receptor. The structure is that of the GluCl α
subunit10 (pdb 3RIF). Left: The full receptor, with two subunits are highlighted; one (blue)
contributes principal agonist binding site residues, found on loops A (red), B (green), and C
(blue). The complementary subunit (black) contributes loops D (purple), E (orange), and F
(yellow). The α-helical region corresponds to the transmembrane domain; the region above
it is extracellular. Right: Detail of agonist binding site, noting approximate locations of key
residues considered here.
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Figure 2.
Chemical structures of drugs and amino acids used in this study. (a) 5-HT3A receptor
antagonists. (b) 5-HT3A receptor agonists. (c) Tryptophan analogs.
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Figure 3.
Dose-response curves of wild-type 5-HT3A receptor. Responses to 5-HT with increasing
concentrations of: (a) ondansetron, and (b) granisetron. Data fit to the Hill equation. Fit
parameters: (a) Mean maximal current: 8 ± 4 μA. [ondansetron] = 0 nM, EC50: 1.3 ± 0.2
μM, nH: 2.4 ± 0.6; [ondansetron] = 0.64 nM, Imax: 63%, EC50: 1.1 ± 0.4 μM, nH: 2 ± 1;
[ondansetron] = 4.5 nM, Imax = 61%, EC50: 9 ± 29 μM, nH: 2 ± 8. (b) Mean maximal
current: 9 ± 4 μA. [granisetron] = 0 nM, EC50: 1.5 ± 0.1 μM, nH: 2.0 ± 0.1; [granisetron] =
0.6 nM, Imax: 25%, EC50: 0.7 ± 0.7 μM, nH: 2 ± 7; [granisetron] = 1.2 nM, Imax: 4%,
EC50: 1 ± 1 μM, nH: 1 ± 2.
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Figure 4.
Representative voltage-clamp traces and dose-inhibition curves for antagonists for wild type
and Trp183 mutant 5-HT3A receptors. Representative traces for inhibition of (a) wild-type
and (b) W183F3W receptors by increasing doses of granisetron. Time of application and
concentration noted by black bars. Channels opened by addition of mCPBG (red bars) at (a)
1 μM and (b) 13 μM. Hashes indicate wash times. Ondansetron inhibition curves shown for
receptors activated by (c) mCPBG, and (d) 5-HT. Granisetron inhibition curves shown for
receptors activated by (e) mCPBG, and (f) 5-HT. Data fit to the Hill equation; fit parameters
(IC50 and nH) are in Table 2.
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Figure 5.
Fluorination plots. Calculated cation-π binding ability versus log[IC50/IC50(wt)] for a series
of fluorinated tryptophan derivatives at Trp183. Ondansetron fluorination plots for receptors
activated by (a) mCPBG, and (b) 5-HT. Granisetron fluorination plots for receptors
activated by (a) mCPBG, and (b) 5-HT. Red lines are linear fits (y = mx + b) inclusive of all
points. Fit parameters (a) m: −0.15 ± 0.03, b: 5.1 ± 0.6, R: 0.94; (b) m: −0.18 ± 0.03, b: 6.0
± 0.8, R: 0.96; (c) m: −0.11 ± 0.04, b: 3 ± 1, R: 0.77; (d) m: −0.14 ± 0.06, b: 5 ± 2, R: 0.82.
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Scheme 1.
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